Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR139 | Q6DWJ6 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.40 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.40 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.39 |
| ▸ | P2RX3 | P56373 | 8/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | P2RX7 | Q99572 | 3/20 | 0.34 |
| ▸ | P2RX2 | Q9UBL9 | 6/20 | 0.34 |
| ▸ | TRPV3 | Q8NET8 | 3/20 | 0.33 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | IDH1 | O75874 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2362685 | 1.00 | GPR139 (0.40) | GPR139CYP2C9NR1I2TRPV4P2RX3 | |
| SCHEMBL998111 | 1.00 | GPR139 (0.40) | GPR139CYP2C9NR1I2TRPV4P2RX3 | |
| SCHEMBL19962272 | 1.00 | GPR139 (0.40) | GPR139CYP2C9NR1I2TRPV4P2RX3 | |
| SCHEMBL998112 | 1.00 | GPR139 (0.40) | GPR139CYP2C9NR1I2TRPV4P2RX3 | |
| SCHEMBL346582 | 1.00 | GPR139 (0.40) | GPR139CYP2C9NR1I2TRPV4P2RX3 | |
| SCHEMBL28656329 | 1.00 | GPR139 (0.40) | GPR139CYP2C9NR1I2TRPV4P2RX3 | |
| SCHEMBL28656330 | 1.00 | GPR139 (0.40) | GPR139CYP2C9NR1I2TRPV4P2RX3 | |
| SCHEMBL14831456 | 0.88 | IDH1 (0.36) | GPR139CYP2C9NR1I2IDH1 | |
| SCHEMBL14831455 | 0.88 | IDH1 (0.36) | GPR139CYP2C9NR1I2IDH1 | |
| SCHEMBL27966106 | 0.88 | IDH1 (0.36) | GPR139CYP2C9NR1I2IDH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220098159-A1 | CARBAMATE DERIVATIVES AND USES THEREOF | NodThera Limited (GB) | 2022-03-31 | — | — | US | disclosed |
| CN-113660983-A | Carbamate derivatives and uses thereof | 诺瑟拉有限公司 | 2021-11-16 | — | — | CN | disclosed |
| EP-2136639-B1 | PYRID-2-YL FUSED HETEROCYCLIC COMPOUNDS, AND COMPOSITIONS AND USES THEREOF | EVOTEC AG (DE) | 2016-03-09 | — | — | EP | disclosed |
| US-8653091-B2 | Pyrid-2yl fused heterocyclic compounds, and compositions and uses thereof | EVOTEC AG (DE) | 2014-02-18 | — | — | US | disclosed |
| US-8653091-B2 | Pyrid-2yl fused heterocyclic compounds, and compositions and uses thereof | EVOTEC AG (DE) | 2014-02-18 | — | — | US | disclosed |
| EP-2139334-B1 | 2-CYANOPHENYL FUSED HETEROCYCLIC COMPOUNDS, AND COMPOSITIONS AND USES THEREOF | EVOTEC AG (DE) | 2013-07-03 | — | — | EP | disclosed |
| US-20120149700-A1 | 2-CYANOPHENYL FUSED HETEROCYCLIC COMPOUNDS, AND COMPOSTIONS AND USES THEREOF | WEI ZHI-LIANG (US) | 2012-06-14 | — | — | US | disclosed |
| US-20120149700-A1 | 2-CYANOPHENYL FUSED HETEROCYCLIC COMPOUNDS, AND COMPOSTIONS AND USES THEREOF | WEI ZHI-LIANG (US) | 2012-06-14 | — | — | US | disclosed |
| US-8076345-B2 | 2-cyanophenyl-7,8-dihydro-5H-pyrido[4,3-d]pyrimidine compounds, compositions and uses thereof | EVOTEC AG (DE) | 2011-12-13 | — | — | US | disclosed |
| US-8076345-B2 | 2-cyanophenyl-7,8-dihydro-5H-pyrido[4,3-d]pyrimidine compounds, compositions and uses thereof | EVOTEC AG (DE) | 2011-12-13 | — | — | US | disclosed |
| US-20110009432-A1 | PYRID-2YL FUSED HETEROCYCLIC COMPOUNDS, AND COMPOSITIONS AND USES THEREOF | EVOTEC AG (DE) | 2011-01-13 | — | — | US | disclosed |
| US-20110009432-A1 | PYRID-2YL FUSED HETEROCYCLIC COMPOUNDS, AND COMPOSITIONS AND USES THEREOF | EVOTEC AG (DE) | 2011-01-13 | — | — | US | disclosed |
| US-20080275037-A1 | 2-Cyanophenyl fused heterocyclic compounds, and compositions and uses thereof | EVOTEC AG (DE) | 2008-11-06 | — | — | US | disclosed |
| US-20080275037-A1 | 2-Cyanophenyl fused heterocyclic compounds, and compositions and uses thereof | EVOTEC AG (DE) | 2008-11-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110009432-A1 | PYRID-2YL FUSED HETEROCYCLIC COMPOUNDS, AND COMPOSITIONS AND USES THEREOF | IL1B, C5, HTR2C | GPR139 1772/4885CYP2C9 269/4885NR1I2 369/4885 |
| US-20220098159-A1 | CARBAMATE DERIVATIVES AND USES THEREOF | CASP1, IL1B, PYCARD | GPR139 1204/4885CYP2C9 579/4885NR1I2 1174/4885 |
| US-20120149700-A1 | 2-CYANOPHENYL FUSED HETEROCYCLIC COMPOUNDS, AND COMPOSTIONS AND USES THEREOF | IL1B, IL1A, CRHR1 | GPR139 1655/4885CYP2C9 216/4885NR1I2 671/4885 |
| US-20080275037-A1 | 2-Cyanophenyl fused heterocyclic compounds, and compositions and uses thereof | CNR2, CNR1, CBR1 | GPR139 1510/4885CYP2C9 436/4885NR1I2 508/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.